GlassScriptPhysician profile
Stephen Suggs
NPI 1689675936
$18,605.16
in general payments reported to CMS, 2019-2025
61 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $13.74 · 2021: $2,003 · 2022: $4,558 · 2023: $4,757 · 2024: $6,838 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,709.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,872.40 | 2021-2024 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $1,253.34 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $995.38 | 2021-2024 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $794.44 | 2022-2024 | Ingrezza, Ongentys |
| Ucb, INC. | $771.84 | 2021-2025 | Rystiggo, Nayzilam, Fintepla |
| Lundbeck LLC | $729.04 | 2021-2024 | Vyepti, Rexulti |
| Mdd US Operations, LLC | $703.39 | 2024 | Gocovri, Apokyn |
| Pfizer INC. | $670.40 | 2023-2024 | |
| Acorda Therapeutics, INC | $654.33 | 2019-2024 | Inbrija, Ampyra |
| Lilly USA, LLC | $646.39 | 2021-2024 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $564.01 | 2022-2024 | |
| Biogen, INC. | $554.59 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Argenx US, INC. | $507.26 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $460.26 | 2021-2024 | Uplizna, Aimovig |
| Impel Pharmaceuticals INC. | $448.58 | 2022-2023 | Trudhesa |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $395.63 | 2021-2023 | Spravato |
| Sk Life Science, INC. | $374.70 | 2022-2024 | |
| Emd Serono, INC. | $307.41 | 2022-2024 | Mavenclad |
| Biohaven Pharmaceutical Holding Company LTD. | $280.46 | 2022 | |
| Tg Therapeutics, INC. | $272.46 | 2023-2024 | |
| Genentech USA, INC. | $242.16 | 2022-2024 | Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $240.98 | 2023-2024 | Nuplazid |
| Csl Behring | $235.65 | 2022-2024 | Hizentra |
| Amneal Pharmaceuticals LLC | $221.53 | 2021-2023 | Rytary |
| Takeda Pharmaceuticals U.S.A., INC. | $216.13 | 2023-2024 | Hyqvia, Gammagard, Trintellix |
| Biohaven Pharmaceuticals, INC. | $205.32 | 2021 | |
| Sumitomo Pharma America, INC. | $201.32 | 2023-2024 | Aptiom |
| Teva Pharmaceuticals USA, INC. | $198.15 | 2020-2024 | Austedo, Austedo Xr, Ajovy |
| Otsuka America Pharmaceutical, INC. | $176.32 | 2023 | Rexulti, Nuedexta |
| Tanabe Pharma America, INC. | $171.48 | 2021-2024 | |
| Catalyst Pharmaceuticals, INC. | $171.10 | 2022-2024 | Firdapse, Fycompa |
| Ani Pharmaceuticals, INC. | $164.52 | 2022-2024 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $162.30 | 2019-2022 | |
| Horizon Therapeutics Plc | $139.74 | 2021-2023 | Uplizna |
| Avanir Pharmaceuticals, INC. | $126.65 | 2022 | |
| Medtronic, INC. | $116.37 | 2021 | |
| Allergan, INC. | $112.45 | 2019-2022 | |
| Kyowa Kirin, INC. | $109.73 | 2022-2024 | Nourianz |
| Portola Pharmaceuticals, LLC | $108.33 | 2019 | |
| Jazz Pharmaceuticals INC. | $99.47 | 2021-2023 | |
| Cycle Pharmaceuticals INC | $90.58 | 2024-2025 | Tascenso Odt, Bafiertam |
| Boston Scientific Corporation | $80.45 | 2022-2025 | Infinion 16 |
| Neurelis, INC. | $71.77 | 2021-2024 | Valtoco |
| Supernus Pharmaceuticals, INC. | $68.55 | 2021-2024 | Qelbree |
| Avion Pharmaceuticals | $62.47 | 2022-2023 | Dhivy |
| Mallinckrodt Hospital Products INC. | $62.29 | 2022 | |
| Genzyme Corporation | $60.67 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $51.86 | 2022 | |
| Celgene Corporation | $51.50 | 2021-2024 | Zeposia |
| Greenwich Biosciences, INC. | $44.26 | 2021 | |
| Banner Life Sciences, LLC | $42.85 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $41.16 | 2024 | |
| Xeris Pharmaceuticals, INC. | $35.73 | 2023-2024 | Keveyis |
| Merz Pharmaceuticals, LLC | $34.47 | 2021-2024 | Inbrija, Xeomin |
| Astrazeneca Pharmaceuticals LP | $28.89 | 2021-2022 | |
| Averitas Pharma INC. | $24.12 | 2023 | Qutenza |
| Kedrion Biopharma, INC. | $21.94 | 2024 | Koate, Kedrab, Gammaked |
| Bioventus LLC | $16.75 | 2024 | L300 Go System |
| Harmony Biosciences LLC | $14.03 | 2021 | |
| Aucta Pharmaceuticals, INC. | $13.49 | 2025 | Motpoly Xr |
| E.R. Squibb & Sons, L.L.C. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Suggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.